Latest News

STAT Plus: Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

A pivot towards reselling Chinese-made coronavirus antibody tests in the U.S. has transformed tiny Aytu Bioscience (AYTU) into an overnight Covid-19 success story, with a soaring share price to match.

But the retail-investor frenzy behind the company’s unprecedented surge since early March disregards numerous risks and red flags. Any or all of them could send its stock price crashing lower. The Covid-19 pandemic has been devastating, but it will end — and so will the stock market bubble in micro-cap companies like Aytu.

Continue to STAT Plus to read the full story…

Source link

Related posts

Understanding Your Health Through Chakras


Atmospheric and environmental changes linked to organ-specific lupus flares


Opinion: Improving the next generation of drugs through patient-centric design for clinical trials


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World